Company news
Nuvalent, Inc. news in 2024
Nuvalent, Inc.'s news releases, calls and decks from 2024, newest first.
Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 18, 2024
Nuvalent Appoints Grant Bogle to Board of Directors
December 8, 2024
Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 25, 2024
Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results
November 11, 2024
Nuvalent Announces Closing of Upsized Public Offering of Common Stock
September 17, 2024
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
September 15, 2024
Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
September 13, 2024
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655
September 12, 2024
Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles
September 8, 2024
Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 28, 2024
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results
August 7, 2024
Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor
July 21, 2024
Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024
July 15, 2024
Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer
July 10, 2024
Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference
May 28, 2024
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
May 15, 2024
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
May 8, 2024
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
April 7, 2024
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024
March 4, 2024
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
February 26, 2024
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
February 26, 2024
Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors
February 11, 2024
Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones
January 7, 2024